Massivemarkets

Nasdaq: EIKN · Listed Feb 5, 2026

Eikon Therapeutics IPO

IPO price

$18.00

Eikon Therapeutics (EIKN) priced its IPO at $18.00 a share and has traded on Nasdaq since Feb 5, 2026.

EIKN today$5.17-71.28%since IPO15-min delayed · as of 7:30:02 PM EST on Nov 18, 2026

See the EIKN quote

First trading day · Feb 5, 2026

IPO price 18.00VWAP 16.08first trade 17.05-5.28% from the IPO pricelow 14.77$14.81volume · rising bars above the line, falling bars below297.72K12:404:00
IPO price
$18.00
the top of the range of $16 to $18
First trade
$17.05
-5.28% from the IPO price
First-day last trade
$14.81
-17.72% from the IPO price, regular session
Raise
$381.2M
before the underwriters' option

These numbers are from the first trading day, Feb 5, 2026.

How EIKN did against the market

EIKN against the market, from its first trade at 12:40 ET to the last trade of the session.

EIKN from its first trade
-13.14%
Against the market (QQQ)
-12.4 pts

EIKN fell 13.1% from its first trade to the last trade of the session. That is 12.4 points worse than the market.

Same-day moves do not show that EIKN caused them. The market is QQQ, the Nasdaq-100 ETF.

The debut race

EIKN against other big listings, as the percent change from each stock's own IPO price.

The first 30 trading days. Each point is the last regular-session trade of a day.

+100%+200%IPOday 1day 5day 10day 15day 20day 25day 30Figma '25 +69.64%Reddit '24 +40.32%CoreWeave '25 +28.42%Arm '23 -3.06%Klarna '25 -7.33%EIKN -39.17%

The IPO scoreboard

EIKN against 6 other big listings: the return from each IPO's own price at the first trade, the close of day 1, day 5, and day 30.

EIKN against other big IPOs: the money raised, and the return from each IPO price at the first trade, at the last trade of day 1, and on day 5 and day 30.
IPORaisedFirst tradeDay 1 closeDay 1 close, as a barDay 5Day 30
Eikon Therapeutics '26$381.2M-5.28%-17.72%-19.06%-39.17%
Figma '25$1.22B+157.58%+252.42%+173.64%+69.64%
Circle '25$1.05B+122.58%+168.45%+278.18%+622.98%
Reddit '24$748M+38.24%+47.97%+69.90%+40.32%
Arm '23$5.23B+10.00%+23.76%+3.63%-3.06%
Klarna '25$1.37B+30.00%+16.14%+13.73%-7.33%
CoreWeave '25$1.5B-2.50%+0.02%+34.32%+28.42%

Day 1 is the last regular-session trade of the first day. Day 5 and day 30 are the last trade of the fifth and thirtieth trading day, counting the listing day as day 1. A cell fills in when that day has traded.

The offering

The Eikon Therapeutics IPO offers 21.18M shares to raise $381.2M, before any underwriters' option.

$14$16$17$18$20
Expected price range
$16 to $18
IPO price
$18.00
Shares offered
21.18M
Money raised
$381.2M
Listing date
Feb 5, 2026
Exchange
Nasdaq
Security
Ordinary Shares

Money raised, against the largest IPOs

  • Alibaba '14$21.77B
  • Facebook '12$18.41B
  • Rivian '21$11.93B
  • Uber '19$8.1B
  • Arm '23$5.23B
  • Eikon Therapeutics$381.2M

Where EIKN ranks

Eikon Therapeutics's market cap against the largest US-listed companies.

Market cap, against the largest US-listed companies

  • AAPL$5.12T
  • MSFT$3.77T
  • NVDA$3.65T
  • GOOGL$3.47T
  • AMZN$2.9T
  • TSM$1.88T
  • AVGO$1.69T
  • META$1.58T
  • TSLA$1.52T
  • BRK.B$1.22T
  • EIKN$280.14M

EIKN news

The latest news and headlines about Eikon Therapeutics (EIKN).

Filings and the company

What Eikon Therapeutics has disclosed to the SEC, and the basic facts about the listing.

8-K filings

Material events that Eikon Therapeutics discloses to the SEC on Form 8-K.

  • Quarterly earningsNov 12, 2026

    On November 12, 2026, Eikon Therapeutics, Inc. issued a press release announcing clinical and corporate updates and its financial results for the quarter ended September 30, 2026 (the "Press Release").

  • Among participants in the squamous cohort, an ORR of 72.4% and a DCR of 100% were observed, respectively, with a median follow-up of 12.7 months and a median duration of response (DOR) of 12.9 months at the efficacy data cutoff. Among participants in the non-squamous cohort, an ORR of 55.6% and a DCR of 80.6% were observed, respectively, with a median follow-up of 17.9 months.

  • “On October 23, 2026, the Company presented initial and updated data for EIK1003 and initial data for EIK1004 and EIK1005 at the 2026 European Society for Medical Oncology Congress.” The filing reports safety, tolerability, pharmacokinetic, objective response, disease-control, and duration-of-response data from multiple Phase 1/2 clinical trial cohorts.

  • Investor presentationAug 14, 2026

    On August 13, 2026, Eikon Therapeutics, Inc. updated its corporate presentation. A copy of the updated presentation is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

  • Director departureAug 3, 2026

    Effective July 31, 2026, Leon Chen, Ph.D. and Joshua Wolfe resigned from the Board of Directors of Eikon Therapeutics, Inc. (the "Company"). Dr. Chen's and Mr. Wolfe's resignations were not because of a disagreement with the Company on any matter relating to the Company's operations, policies or practices.

About Eikon Therapeutics

Eikon Therapeutics Inc is a late-stage clinical biopharmaceutical company dedicated to building a world-wide , fully-integrated organization developing important, medicines to address serious unmet medical needs. It operates in a single operating segment, which is in the business of drug discovery leveraging its proprietary technology and clinical development of its product candidates. Its product candidates include: EIK1001, EIK1003, EIK1004, EIK1005, and EIK1006.

Ticker
EIKN
Exchange
Nasdaq
Market
stocks
Type
CS
Currency
USD
Industry
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Employees
384
Listed
Feb 5, 2026
Security
Ordinary Shares
Company website

Frequently asked questions

What was the Eikon Therapeutics IPO price?

$18.00 a share.

When did Eikon Therapeutics go public?

Eikon Therapeutics listed on Nasdaq on Feb 5, 2026 under the ticker EIKN.

How much did the Eikon Therapeutics IPO raise?

$381.2M, before any underwriters' option.

How did Eikon Therapeutics open on its first day?

EIKN first traded at $17.05, -5.28% from the IPO price of $18.00.

How did EIKN close on its first day?

Its last regular-session trade was $14.81, -17.72% from the IPO price of $18.00.

What was the EIKN first-day trading range?

$14.37 to $17.40 in the regular session.

How many EIKN shares traded on the first day?

4.41M shares in the regular session.

How many shares did Eikon Therapeutics sell in its IPO?

21.18M shares.

How did EIKN do against the market on its first day?

EIKN fell 13.1% from its first trade to the last trade of the session. That is 12.4 points worse than the market (QQQ, the Nasdaq-100 ETF).

What exchange is EIKN listed on?

Eikon Therapeutics lists on Nasdaq under the ticker EIKN.

Build with Massive

Get the EIKN data behind this page

The Massive endpoint behind each section of this page
What the page showsEndpoint
Offering terms and dates/vX/reference/ipos
Price/v3/snapshot
Chart, VWAP, and the market comparison/v2/aggs/ticker/EIKN/range/5/minute
Market cap/v3/reference/tickers/EIKN
News/v2/reference/news
Filings/vX/disclosures

Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.